ROCKVILLE, Md.--(BUSINESS WIRE)--Omnia Biologics, Inc. (Rockville, MD) and Sumagen Co., Ltd. (London, ON) today jointly announced the successful completion of cGMP manufacture of Sumagen’s HIV/AIDS vaccine for a Phase I clinical trial. Safe, effective vaccines for HIV prophylaxis and therapy remain a vital and elusive goal in the fight against infectious disease. The need for new clinical candidates for HIV/AIDS is pressing since recent failures of other late stage products.
